Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.
Company Details
- Employees
- 40
- Founded
- -
- Address
- 北京市北京经济技术开发区经海三路105号院8号楼, 北京市,北京市 101111,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://jacobiopharma.com
- Keywords
- Durham.
- HQ
- 北京市, 北京市
Jacobio Pharma Questions
Jacobio Pharma's website is http://jacobiopharma.com
Jacobio Pharma's LinkedIn profile is https://www.linkedin.com/company/jacobio-pharma
Jacobio Pharma has
40 employees.
View email and phone details for 40
employees at Jacobio Pharma.
Jacobio Pharma's industry is
Biotechnology Research
Jacobio Pharma's top competitors are
Addex Therapeutics,
Innovent Biologics,
Innocare Pharma,
Haya Therapeutics,
Yoltech Therapeutics,
Salubris Pharmaceuticals Co.,ltd.,
Lindy Biosciences, Inc.,
Neox Biotech,
Shanghai Allist Pharmaceuticals Co., Ltd,
Quotient Therapeutics.
Jacobio Pharma's categories are Biotechnology Research
Jacobio Pharma's founding year is 2015
